Raynaud Phenomenon in Antisynthetase Syndrome Treated With Epoprostenol

From the ∗Departments of Internal Medicine †Pathology ‡Pulmonology and Critical Care Medicine, University of Cincinnati Medical Center, Cincinnati, OH. The authors have no financial disclosures. It should be noted that this represents an off-label use of epoprostenol. Currently, it is only Food and Drug Administration approved in the United States for the treatment of pulmonary artery hypertension, and not as a treatment for Raynaud phenomenon. The authors have no conflicts of interest related to this topic. Correspondence: Eric Vick, MD, PhD, Department of Internal Medicine, University of Cincinnati Medical Center, Medical Sciences Building Room 6056, 231 Albert B. Sabin Way, Cincinnati, OH 45267-0557. E-mail: [email protected].